Roland Diggelmann resigns as CEO of Roche Diagnostics after 10 years

By Sophie Chapman
The Chief Executive Officer of the Swizerland-based drugmaker, Roche Diagnostics, has announced his resignation. Ronald Diggelmann will leave the compa...

The Chief Executive Officer of the Swizerland-based drugmaker, Roche Diagnostics, has announced his resignation.

Ronald Diggelmann will leave the company next month following working for the firm for a decade.

The CEO, 51, joined Roche Diagnostics’ parent company, Roche, in 2008. Digglemann has worked for the diagnostics unit since 2012.

Prior to his role as CEO, Diggelmann was appoint as the Region Head of Asia Pacific for Roche Diagnostics.

Michael Heuer, the firm’s Region Head of Europe, Middle East, Africa, and Latin America, will be appoint the interim CEO in September.

SEE ALSO:

“I am grateful to Roland Diggelmann for his many valuable contributions during his 10 years at Roche and I wish him all the best for the future,” stated Severin Schwan, CEO of Roche.

“I am pleased to appoint Michael Heuer as interim CEO of our Diagnostics Division.”

“Michael is a very respected leader with a wealth of experience in diagnostics.”

Heuer has worked in sales, marketing, and product develop positions in Europe and the US.

The soon-to-be CEO has also held the position of Head of Roche Near Patient Testing Business Area.

Share

Featured Articles

McKinsey: Women More Likely to die of Heart Attack Than Men

McKinsey Health Institute's Lucy Pérez says cardiovascular disease top killer of women yet physicians don't know their heart attack symptoms are different

Novo Nordisk Buys $1bn Cardior in CardioVascular Move

As Novo Nordisk expands into heart medicines, we profile the Danish pharma giant who in 1923 was the first to make insulin commercially available

Shoddy Chinese Syringes Sees BD Ramp-up Production

Becton Dickinson – a major supplier of syringes – said it has upped manufacturing in its US facilities after FDA warning on China-made products

AI Tool 'Picks up Early-stage Breast Cancers Doctors Missed'

Technology & AI

AstraZeneca Buys $2bn Fusion in Next-gen Cancer Drugs Move

Medical Devices & Pharma

Eli Lilly and Amazon Pharmacy Partner on Drugs Delivery

Digital Healthcare